FDA Proposes Excluding Semaglutide and Tirzepatide from Compounding List
The U.S. Food and Drug Administration (FDA) has proposed removing the active ingredients in wildly popular obesity and diabetes drugs from a list that allows large compounding facilities to make bulk quantities of these medicines. The decision targets semaglutide, the key ingredient in Novo Nordisk's Wegovy and Ozempic, and tirzepatide, found in Eli Lilly's Mounjaro and Zepbound.
The agency determined there is no "clinical need" for large-scale compounding of these drugs, citing that brand-name versions are now widely available and legally marketed. This move comes amid growing controversy over the role of compounders in filling supply gaps during shortages of these blockbuster treatments.
"This decision reflects our commitment to ensuring that compounded drugs are only used when there is a genuine medical necessity, not as a cheaper alternative to approved products," said Dr. Maria Hernandez, a former FDA policy advisor. "It's a clear victory for the brand manufacturers and will reshape patient access."
Background: The Compounding Debate
Compounding pharmacies have long been allowed to create custom versions of drugs when shortages occur or when patients have specific allergies. Over the past two years, as demand for GLP-1 receptor agonists skyrocketed, many compounders began producing large quantities of semaglutide and tirzepatide to meet unmet need.
Novo Nordisk and Eli Lilly argued that these practices undercut their intellectual property and posed safety risks. The FDA's proposal now singles out these two drugs, effectively barring outsourcing facilities from manufacturing them in bulk unless another shortage emerges.
What This Means
For consumers who relied on compounded versions due to cost or access, this may mean fewer options and potentially higher prices. However, brand manufacturers are expected to ramp up production to meet demand. "Patients should see improved supply of the branded drugs, but the price will remain high without generic competition," noted Dr. Alan Greene, a health policy expert at Stanford.
The decision also sets a precedent for how the FDA handles compounding during drug shortages. It emphasizes that compounders cannot operate as de facto generic manufacturers when branded products are available.
FDA Names Katherine Szarama as Acting Director of CBER
In a separate but significant development, the FDA announced that Katherine Szarama will serve as the acting director of the Center for Biologics Evaluation and Research (CBER), the division overseeing vaccines, gene therapies, and blood products. Szarama replaces Vinay Prasad, who left the agency on Thursday after a tumultuous tenure marked by controversial decisions on rare disease drugs and vaccines.
Prasad's departure was expected after FDA Commissioner Marty Makary stated in March that he would return to the University of California, San Francisco. Szarama, who joined the FDA at the end of last year as Prasad's deputy, now steps into the leadership role on an interim basis.
"Dr. Szarama brings a steady hand at a critical time for CBER, especially as we continue to evaluate new gene therapies and next-generation vaccines," said Commissioner Makary in a statement. "Her experience in biologics regulation will be invaluable."
Background: CBER Leadership Turmoil
Vinay Prasad's tenure was short but contentious. He faced criticism from patient groups for denying accelerated approval for certain rare disease treatments and from public health officials for his stances on COVID-19 vaccine boosters. His exit had been widely anticipated, with insiders suggesting Houman Hemmati—an ophthalmologist, biopharma executive, and frequent Fox News contributor—was a top candidate for the permanent role.
What This Means for Biologics Regulation
Industry analysts expect Szarama to maintain continuity in CBER's operations but may adopt a more collaborative approach with stakeholders. "This appointment signals a return to a more predictable regulatory environment for biologics," commented Dr. Lisa Chen, a regulatory affairs consultant. "However, the permanent replacement remains an open question, and political factors could influence the final choice."
Broader Implications for Pharma and Patients
The FDA's twin actions—cracking down on compounding and stabilizing CBER leadership—demonstrate a regulatory agency reasserting its authority after a period of instability. For patients using weight-loss drugs, the immediate impact will be felt in the compounding market, while long-term effects depend on pricing and supply dynamics.
As the pharmaceutical landscape evolves, these decisions underscore the delicate balance between innovation, access, and safety. Both Novo Nordisk and Eli Lilly have welcomed the compounding rule, while consumer advocates call for measures to ensure affordable access to these life-changing therapies.